Jie Su

Jie Su

Auto-generated profile, based on publicly available information

Jie Su

Department of Medical Biochemistry and Biophysics, Division of Molecular Neurobiology, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
GWGustaf Wigerblad
Gustaf Wigerblad
DBDuygu B Bas
Duygu B Bas
CFCátia Fernades-Cerqueira
Cátia Fernades-Cerqueira
AKAkilan Krishnamurthy
Akilan Krishnamurthy
Kutty Selva NandakumarKutty Selva Nandakumar
Kutty Selva Nandakumar
CSCamilla I. Svensson
Camilla I. Svensson
Objective An interesting and so far unexplained feature of chronic pain in autoimmune disease is the frequent disconnect between pain and inflammation. This is illustrated well in rheumatoid arthritis (RA) where pain in joints (arthralgia) may precede joint inflammation and persist even after successful anti-inflammatory treatment. In the present study, we have addressed the possibility that autoantibodies against citrullinated proteins (ACPA), present in RA, may be directly responsible for the induction of pain, independent of inflammation. Methods Antibodies purified from human patients with RA, healthy donors and murinised monoclonal ACPA were injected into mice. Pain-like behaviour was monitored for up to 28 days, and tissues were analysed for signs of pathology. Mouse osteoclasts were cultured and stimulated with antibodies, and supernatants analysed for release of factors. Mice were treated with CXCR1/2 (interleukin (IL) 8 receptor) antagonist reparixin. Results Mice injected with either human or murinised ACPA developed long-lasting pronounced pain-like behaviour in the absence of inflammation, while non-ACPA IgG from patients with RA or control monoclonal IgG were without pronociceptive effect. This effect was coupled to ACPA-mediated activation of osteoclasts and release of the nociceptive chemokine CXCL1 (analogue to human IL-8). ACPA-induced pain-like behaviour was reversed with reparixin. Conclusions The data suggest that CXCL1/IL-8, released from osteoclasts in an autoantibody-dependent manner, produces pain by activating sensory neurons. The identification of this new pain pathway may open new avenues for pain treatment in RA and also in other painful diseases associated with autoantibody production and/or osteoclast activation.

1 September 2014 in Pain
Verified
Journal Article
Closed access
NANilesh M. Agalave
Nilesh M. Agalave
MLMax Larsson
Max Larsson
SASally Abdelmoaty
Sally Abdelmoaty
JSJie Su
Jie Su
ABAzar Baharpoor
Azar Baharpoor
CSCamilla I. Svensson
Camilla I. Svensson
Extracellular high mobility group box-1 protein (HMGB1) plays important roles in the pathogenesis of nerve injury- and cancer-induced pain. However, the involvement of spinal HMGB1 in arthritis-induced pain has not been examined previously and is the focus of this study. Immunohistochemistry showed that HMGB1 is expressed in neurons and glial cells in the spinal cord. Subsequent to induction of collagen antibody-induced arthritis (CAIA), Hmgb1 mRNA and extranuclear protein levels were significantly increased in the lumbar spinal cord. Intrathecal (i.t.) injection of a neutralizing anti-HMGB1 monoclonal antibody or recombinant HMGB1 box A peptide (Abox), which each prevent extracellular HMGB1 activities, reversed CAIA-induced mechanical hypersensitivity. This occurred during ongoing joint inflammation as well as during the postinflammatory phase, indicating that spinal HMGB1 has an important function in nociception persisting beyond episodes of joint inflammation. Importantly, only HMGB1 in its partially oxidized isoform (disulfide HMGB1), which activates toll-like receptor 4 (TLR4), but not in its fully reduced or fully oxidized isoforms, evoked mechanical hypersensitivity upon i.t. injection. Interestingly, although both male and female mice developed mechanical hypersensitivity in response to i.t. HMGB1, female mice recovered faster. Furthermore, the pro-nociceptive effect of i.t. injection of HMGB1 persisted in Tlr2- and Rage-, but was absent in Tlr4-deficient mice. The same pattern was observed for HMGB1-induced spinal microglia and astrocyte activation and cytokine induction. These results demonstrate that spinal HMGB1 contributes to nociceptive signal transmission via activation of TLR4 and point to disulfide HMGB1 inhibition as a potential therapeutic strategy in treatment of chronic inflammatory pain.

29 August 2012 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
DBDuygu B. Bas
Duygu B. Bas
JSJie Su
Jie Su
KSKatalin Sandor
Katalin Sandor
NANilesh M. Agalave
Nilesh M. Agalave
JLJohanna Lundberg
Johanna Lundberg
CSCamilla I. Svensson
Camilla I. Svensson
Objective: Pain is one of the most debilitating symptoms reported by rheumatoid arthritis (RA) patients. While the collagen antibody–induced arthritis (CAIA) model is used for studying the effector phase of RA pathologic progression, it has not been evaluated as a model for studies of pain. Thus, this study was undertaken to examine pain‐like behavior induced by anticollagen antibodies and to assess the effect of currently prescribed analgesics for RA. In addition, the involvement of spinal glia in antibody‐induced pain was explored.Methods: CAIA was induced in mice by intravenous injection of a collagen antibody cocktail, followed by intraperitoneal injection of lipopolysaccharide. Disease severity was assessed by visual and histologic examination. Pain‐like behavior and the antinociceptive effect of diclofenac, buprenorphine, gabapentin, pentoxifylline, and JNK‐interacting protein 1 were examined in mechanical stimulation experiments. Spinal astrocyte and microglia reactivity were investigated by real‐time polymerase chain reaction and immunohistochemistry.Results: Following the induction of CAIA, mice developed transient joint inflammation. In contrast, pain‐like behavior was observed prior to, and outlasted, the visual signs of arthritis. Whereas gabapentin and buprenorphine attenuated mechanical hypersensitivity during both the inflammatory and postinflammatory phases of arthritis, diclofenac was antinociceptive only during the inflammatory phase. Spinal astrocytes and microglia displayed time‐dependent signs of activation, and inhibition of glial activity reversed CAIA‐induced mechanical hypersensitivity.Conclusion: CAIA represents a multifaceted model for studies exploring the mechanisms of pain induced by inflammation in the articular joint. Our findings of a time‐dependent prostaglandin and spinal glial contribution to antibody‐induced pain highlight the importance of using appropriate disease models to assess joint‐related pain.

18 April 2016 in Pain Management
Verified
Journal Article
Closed access
DBDuygu B Bas
Duygu B Bas
JSJie Su
Jie Su
GWGustaf Wigerblad
Gustaf Wigerblad
CSCamilla I. Svensson
Camilla I. Svensson
Pain is one of the most challenging symptoms for patients with rheumatoid arthritis (RA). RA-related pain is frequently considered to be solely a consequence of inflammation in the joints; however, recent studies show that multiple mechanisms are involved. Indeed, RA pain may start even before the disease manifests, and frequently does not correlate with the degree of inflammation or pharmacological management. In this aspect, animal studies have the potential to provide new insights into the pathology that initiate and maintain pain in RA. The focus of this review is to describe the most commonly used animal models for studies of RA pathology, which have also been utilized in pain research, and to summarize findings providing potential clues to the mechanisms involved in the regulation of RA-induced pain.

8 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YHYibo He
Yibo He
CGChangrong Ge
Changrong Ge
ÀMÀlex Moreno-Giró
Àlex Moreno-Giró
BXBingze Xu
Bingze Xu
CBChristian Michel Beusch
Christian Michel Beusch
Rikard HolmdahlRikard Holmdahl
Rikard Holmdahl
Although elevated levels of anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis (RA), the in vivo functions of these antibodies remain unclear. Here, we have expressed monoclonal ACPAs derived from patients with RA, and analyzed their functions in mice, as well as their specificities. None of the ACPAs showed arthritogenicity nor induced pain-associated behavior in mice. However, one of the antibodies, clone E4, protected mice from antibody-induced arthritis. E4 showed a binding pattern restricted to skin, macrophages and dendritic cells in lymphoid tissue, and cartilage derived from mouse and human arthritic joints. Proteomic analysis confirmed that E4 strongly binds to macrophages and certain RA synovial fluid proteins such as α-enolase. The protective effect of E4 was epitope-specific and dependent on the interaction between E4-citrullinated α-enolase immune complexes with FCGR2B on macrophages, resulting in increased IL-10 secretion and reduced osteoclastogenesis. These findings suggest that a subset of ACPAs have therapeutic potential in RA.

29 January 2015 in Journal of Comparative Neurology
Verified
Journal Article
Closed access
PDF file
JSJie Su
Jie Su
GTGao Tian-Le
Gao Tian-Le
TSTiejun Shi
Tiejun Shi
QXQiong Xiang
Qiong Xiang
XXXiaojun Xu
Xiaojun Xu
CSCamilla I. Svensson
Camilla I. Svensson